. 2011 Aug 18;6(8):e23014. doi: 10.1371/journal.pone.0023014

Table 2. Properties of C. difficile strains used in this study.

Strain	Ribotype^*	Other strain information^†	Place of isolation, date	Clinical details	Source
630	012	Tc^R Erm^R	Zurich, Switzerland, 1982	pseudomembraneous colitis	[44]
R20291	027	Tc^S Erm^S	Stoke Mandeville Hospital, UK, 2006		[45]
CD196	027		Paris, France, 1985
ATCC43255 (VPI10463)	087
QCD-23M63	078	Toxinotype V, Tc^S Erm^S	Montreal, Quebec, Canada	Severe CDAD	Dr. A. Dascal
QCD-32G58	027	NAP1, Binary toxin +ve, tcdC 18 bp deletion, Tc^S Erm^R	Quebec, Canada, 2004–8	CDAD	Dr. A. Dascal
QCD-37X79	027	NAP1a/001	London, Ontario Canada, 2005	Severe CDAD	Dr. A. Dascal
QCD-63Q42	001	NAP2	Quebec City, Quebec, Canada, 2005	Severe CDAD	Dr. A. Dascal
QCD-66C26	027	NAP1, Binary toxin +ve, tcdC delta-117 and 18 bp deletion, Tc^S Erm^R	Quebec, Canada, 2004–8	CDAD	Dr. A. Dascal
QCD-76W55	027	NAP1	Minnesota, Minneapolis, US, 1988		Dr. A. Dascal
QCD-97B34	027	NAP1b/006	St. John's, Newfoundland, Canada, 2004	Severe CDAD	Dr. A. Dascal

Tc: tetracycline, Erm: erythromycin, ^S: sensitive, ^R: resistant.

*not determined, ribotype equivalent,

^†

Toxinotype [46]; NAP. North American PFGE type [4]; tcdC 18 bp deletion, tcdC delta-117 [47].